147 related articles for article (PubMed ID: 26384467)
1. Is there a place for cytoreduction in metastatic prostate cancer?
Reeves F; Costello AJ
BJU Int; 2016 Jul; 118(1):14-5. PubMed ID: 26384467
[No Abstract] [Full Text] [Related]
2. Difference of opinion - Radical prostatectomy in metastatic prostate cancer: is there enough evidence? | Opinion: Yes.
Costa WH; Guimarães GC
Int Braz J Urol; 2016; 42(5):876-879. PubMed ID: 27716456
[No Abstract] [Full Text] [Related]
3. Difference of opinion - Radical prostatectomy in metastatic prostate cancer: is there enough evidence? | Opinion: No.
Ristau BT; Smaldone MC
Int Braz J Urol; 2016; 42(5):880-882. PubMed ID: 27716457
[No Abstract] [Full Text] [Related]
4. Cytoreductive prostatectomy in metastatic prostate cancer: a systematic review.
Becker JA; Berg KD; Røder MA; Brasso K; Iversen P
Scand J Urol; 2018 Feb; 52(1):1-7. PubMed ID: 28818014
[TBL] [Abstract][Full Text] [Related]
5. [Cytoreductive, radical prostatectomy in metastatic prostate cancer].
Chaloupka M; Herlemann A; Spek A; Gratzke C; Stief C
Urologe A; 2017 Nov; 56(11):1430-1434. PubMed ID: 28983651
[TBL] [Abstract][Full Text] [Related]
6. The presence of high-grade prostatic intraepithelial neoplasia or atypia on prostate biopsy does not adversely affect prostatectomy outcomes for patients otherwise eligible for active surveillance.
Pietzak EJ; Kabarriti AE; Mucksavage P; Bavaria T; Van Arsdalen K; Malkowicz SB; Wein AJ; Guzzo TJ
Urology; 2014 Dec; 84(6):1442-7. PubMed ID: 25288572
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer mortality is high in the elderly and can be reduced by selective individualized curative treatment.
Moretti K; Vatandoust S; Kichenadasse G; O'Callaghan ME; Vincent AD; Kopsaftis T; Walsh S; Borg M; Karapetis C
World J Urol; 2018 Nov; 36(11):1799-1800. PubMed ID: 29748854
[No Abstract] [Full Text] [Related]
8. Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense?
Mathieu R; Korn SM; Bensalah K; Kramer G; Shariat SF
World J Urol; 2017 Apr; 35(4):567-577. PubMed ID: 27502935
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer.
D'Amico AV; Chen MH
J Clin Oncol; 2009 Aug; 27(22):3575-6. PubMed ID: 19506151
[No Abstract] [Full Text] [Related]
10. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.
Heidenreich A; Pfister D; Porres D
J Urol; 2015 Mar; 193(3):832-8. PubMed ID: 25254935
[TBL] [Abstract][Full Text] [Related]
11. New surgical approaches for clinically high-risk or metastatic prostate cancer.
Dell'Oglio P; Stabile A; Gandaglia G; Zaffuto E; Fossati N; Bandini M; Suardi N; Karakiewicz PI; Shariat SF; Montorsi F; Briganti A
Expert Rev Anticancer Ther; 2017 Nov; 17(11):1013-1031. PubMed ID: 28862047
[TBL] [Abstract][Full Text] [Related]
12. Surgical cytoreduction of the primary tumor reduces metastatic progression in a mouse model of prostate cancer.
Cifuentes FF; Valenzuela RH; Contreras HR; Castellón EA
Oncol Rep; 2015 Dec; 34(6):2837-44. PubMed ID: 26503286
[TBL] [Abstract][Full Text] [Related]
13. Classification system: organ preserving treatment for prostate cancer.
Ward JF; Jones JS
Urology; 2010 Jun; 75(6):1258-60. PubMed ID: 20080292
[No Abstract] [Full Text] [Related]
14. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
15. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006.
Abdollah F; Sun M; Thuret R; Jeldres C; Tian Z; Briganti A; Shariat SF; Perrotte P; Rigatti P; Montorsi F; Karakiewicz PI
Eur Urol; 2011 Jan; 59(1):88-95. PubMed ID: 20965646
[TBL] [Abstract][Full Text] [Related]
16. The devil is in the details.
Eastham JA; Scardino PT
Eur Urol; 2011 May; 59(5):708-9; discussion 710-1. PubMed ID: 21315503
[No Abstract] [Full Text] [Related]
17. Words of wisdom. Re: Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases--results of a feasibility and case-control study.
Satkunasivam R; Aron M
Eur Urol; 2015 Mar; 67(3):589-90. PubMed ID: 25760411
[No Abstract] [Full Text] [Related]
18. Oncologic outcomes at 10 years following robotic radical prostatectomy.
Diaz M; Peabody JO; Kapoor V; Sammon J; Rogers CG; Stricker H; Lane Z; Gupta N; Bhandari M; Menon M
Eur Urol; 2015 Jun; 67(6):1168-1176. PubMed ID: 24996687
[TBL] [Abstract][Full Text] [Related]
19. Natural history of patients presenting biochemical recurrence after radical prostatectomy: some good news?
Guillonneau BD; Fizazi K
Eur Urol; 2011 Jun; 59(6):900-1. PubMed ID: 21419564
[No Abstract] [Full Text] [Related]
20. NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.
Moul JW; Sarno MJ; McDermed JE; Triebell MT; Reynolds MA
Urology; 2014 Dec; 84(6):1427-32. PubMed ID: 25432832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
